Insider Buying: Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Buys 20,000 Shares of Stock

Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman acquired 20,000 shares of Medicenna Therapeutics stock in a transaction that occurred on Thursday, January 9th. The stock was bought at an average price of C$1.45 per share, with a total value of C$29,000.00.

Medicenna Therapeutics Price Performance

Shares of MDNA stock traded down C$0.01 during midday trading on Friday, reaching C$1.44. 48,584 shares of the company traded hands, compared to its average volume of 64,551. The firm has a market cap of C$110.06 million, a PE ratio of -3.79 and a beta of 1.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.51 and a quick ratio of 4.65. The firm’s 50 day simple moving average is C$1.80 and its two-hundred day simple moving average is C$2.01. Medicenna Therapeutics Corp. has a 1-year low of C$0.40 and a 1-year high of C$2.98.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.